{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:04:24Z","timestamp":1791921864393,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA023108"],"award-info":[{"award-number":["5P30CA023108"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009230","name":"Norris Cotton Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017040","name":"Dartmouth SYNERGY Clinical and Translational Science Institute","doi-asserted-by":"publisher","award":["UL1TR001086"],"award-info":[{"award-number":["UL1TR001086"]}],"id":[{"id":"10.13039\/100017040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clcc.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T12:55:29Z","timestamp":1652273729000},"page":"e189-e195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-9995","authenticated-orcid":false,"given":"Gabriel A.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan T.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Busam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna N.A.","family":"Tosteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2022.05.001_bib0001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clon.2017.03.001","article-title":"Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a cancer care ontario systematic review","volume":"29","author":"Meyers","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clcc.2022.05.001_bib0002","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/OP.20.00553","article-title":"All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide","volume":"16","author":"Innocenti","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clcc.2022.05.001_bib0003","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.05.001_bib0004","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clcc.2022.05.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2022.05.001_bib0006","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clcc.2022.05.001_bib0007","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","article-title":"Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis","volume":"32","author":"Rosmarin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0020","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/onco.13967","article-title":"Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis","volume":"26","author":"Sharma","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2022.05.001_bib0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2022.05.001_bib0011","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2022.05.001_bib0012","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2022.05.001_bib0013","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","article-title":"Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach","volume":"44","author":"Boisdron-Celle","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","article-title":"Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time","volume":"54","author":"Lunenburg","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2022.05.001_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2013explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clcc.2022.05.001_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000197","article-title":"Association between DPYD c.1129-5923 C>G\/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)","volume":"26","author":"Lee","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clcc.2022.05.001_bib0018","unstructured":"ARUP Laboratories. Dihydropyrimidine Dehydrogenase (DPYD), 3 Variants. Vol 2021."},{"key":"10.1016\/j.clcc.2022.05.001_bib0019","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cpt.1257","article-title":"The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice","volume":"105","author":"Toffoli","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clcc.2022.05.001_bib0021","year":"2019"},{"key":"10.1016\/j.clcc.2022.05.001_bib0022","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(95)90696-7","article-title":"Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2022.05.001_bib0023","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11136-010-9589-5","article-title":"Preference values associated with stage III colon cancer and adjuvant chemotherapy","volume":"19","author":"Best","year":"2010","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clcc.2022.05.001_bib0024","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1294::AID-CNCR4>3.0.CO;2-M","article-title":"Quality of life in survivors of colorectal carcinoma","volume":"88","author":"Ramsey","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clcc.2022.05.001_bib0025","unstructured":"CMS.gov: Clinical Laboratory Fee Schedule Files. Vol 2021."},{"key":"10.1016\/j.clcc.2022.05.001_bib0026","first-page":"152","article-title":"Inpatient hospitalization costs associated with nausea and vomiting among patients with cancer","author":"Roeland","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0027","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2022.05.001_bib0028","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: a review of measures for health services research in the United States","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.clcc.2022.05.001_bib0029","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/COC.0000000000000231","article-title":"Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States","volume":"41","author":"Shankaran","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0030","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.2016-0455","article-title":"Bevacizumab for metastatic colorectal cancer: a global cost-effectiveness analysis","volume":"22","author":"Goldstein","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2022.05.001_bib0031","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jamaoncol.2018.5070","article-title":"Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer","volume":"5","author":"Sherman","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0032","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","article-title":"A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy","volume":"107","author":"Henricks","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2022.05.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/1559325818803042","article-title":"Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience","volume":"16","author":"Murphy","year":"2018","journal-title":"Dose Response"},{"key":"10.1016\/j.clcc.2022.05.001_bib0034","first-page":"1","article-title":"DPYD genotyping in patients who have planned cancer treatment with fluoropyrimidines: a health technology assessment","volume":"21","year":"2021","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.clcc.2022.05.001_bib0035","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/pgs-2016-0006","article-title":"Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines","volume":"17","author":"Cortejoso","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clcc.2022.05.001_bib0036","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/PO.20.00513","article-title":"Integrating somatic and germline next-generation sequencing into routine clinical oncology practice","author":"Hicks","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clcc.2022.05.001_bib0037","unstructured":"European Medicines Agency. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Vol 2021."},{"key":"10.1016\/j.clcc.2022.05.001_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.626954","article-title":"Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations","volume":"12","author":"da Rocha","year":"2021","journal-title":"Front Genet"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282200055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282200055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:08Z","timestamp":1761520148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282200055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S153300282200055X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2022.05.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}